Yolo Group serves millions of users globally with gaming experiences and operates an ecosystem behind its brands.

Yolo Group

An independent video game development company focused on creating innovative, player-focused experiences.

Gunzilla

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Voyager Therapeutics, Inc.

Mimimi Games is an independent game studio that develops real-time tactics and stealth strategy games, including unique titles like Shadow Tactics and Desperados III. The studio was self-described to innovate in its genre while maintaining core gameplay elements.

Metric
Company Name	Yolo Group	Gunzilla	Voyager Therapeutics, Inc.	Mimimi Games
Symbol			VYGR
MSH ID	COM:YOLO	COM:GUNZILLAGAMES	COM:VOYAGERTHERAPEUTICS	GAMES:MIMIMI
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Consumer Services	Technology	Healthcare	Technology
Industry	Gambling & Casinos	Video game industry	Biotechnology	Video Games
Country	DE	DE	US	DE
Stage
Employee Count		254	162
Website	yolo.com	gunzillagames.com	voyagertherapeutics.com	mimimi.games
LinkedIn		gunzilla-games
Founders

Metric
Market Cap			439.50M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			250.01M
Revenue (LTM)
Revenue (NTM)
Gross Profit			245.57M
EBITDA			126.45M
Operating Income			122.01M
Net Income			132.33M
EPS			3.08
Diluted EPS			2.97
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.98
Operating Profit Margin			0.49
EBITDA Margin			0.51
Net Profit Margin			0.53
Return on Equity			0.64
Return on Assets			0.38
Return on Capital Employed			0.43

COM:YOLO

Yolo Group

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			6.18
P/B Ratio			1.84
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			4.34
EV Multiple			4.40

Metric
Days Sales Outstanding			9.99
Days Payables Outstanding
Days Inventory Outstanding			0.00
Operating Cycle			123.30
Cash Conversion Cycle			-8.53
Asset Turnover			0.71

Metric
Operating Cash Flow			77.92M
Free Cash Flow			74.66M
Cash Flow to Debt			3.74
Operating Cash Flow/Sales			0.30
Free Cash Flow Yield			0.25

Metric
Cash & Equivalents			68.80M
Accounts Receivable			-83.23M
Inventory
Goodwill
Debt to Capitalization			0.12
Debt to Assets			0.07
Current Ratio			4.25
Quick Ratio			9.51

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.09
R&D to Revenue			0.68
SG&A to Revenue			0.29